- JP-listed companies
- Kidswell Bio Corporation
Kidswell Bio CorporationJP:4584
Market cap
¥10.1B
P/E ratio
| Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | |
| Net sales of finished goods | 31 | 289 | 322 | 1,101 | 1,003 | 908 | 907 | - | - | - | 2,331 |
| Intellectual property revenue | - | - | - | 60 | 86 | 122 | 113 | - | - | - | 248 |
| Service revenue | 30 | 12 | - | - | - | 30 | 2 | - | - | - | 196 |
| Net sales | 61 | 301 | 322 | 1,161 | 1,089 | 1,060 | 1,022 | 1,078 | 997 | 1,569 | 2,776 |
| Beginning finished goods inventory | - | - | - | - | - | - | - | - | - | - | 200 |
| Cost of products manufactured | - | 132 | 148 | 501 | 397 | 422 | 412 | - | - | - | 1,263 |
| Total | - | 132 | 148 | 501 | 397 | 422 | 412 | - | - | - | 1,464 |
| Ending finished goods inventory | - | - | - | - | - | - | - | - | - | - | 213 |
| Cost of finished goods sold | - | 132 | 148 | 501 | 397 | 422 | 412 | - | - | - | 1,251 |
| Cost of sales | 15 | 142 | 148 | 501 | 397 | 422 | 412 | 653 | 120 | 550 | 1,251 |
| Gross profit (loss) | 45 | 159 | 174 | 660 | 692 | 637 | 609 | 425 | 877 | 1,019 | 1,526 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | - | - | - | 1 |
| Research and development expenses | 206 | 413 | 690 | 1,075 | 1,433 | 1,107 | 945 | 898 | 964 | 1,150 | 1,216 |
| Royalty fee | - | - | - | - | - | - | - | - | - | - | 183 |
| Salaries and allowances | - | - | - | - | - | - | 120 | 188 | 247 | 267 | 256 |
| Other | 197 | 259 | 308 | 405 | 443 | 443 | 469 | 495 | 631 | 505 | 421 |
| Selling, general and administrative expenses | 404 | 672 | 998 | 1,480 | 1,877 | 1,551 | 1,415 | 1,586 | 1,847 | 1,938 | 2,077 |
| Operating profit (loss) | -358 | -512 | -824 | -820 | -1,184 | -913 | -806 | -1,161 | -970 | -919 | -551 |
| Interest income | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gain on sales of materials | - | - | - | 16 | 14 | 3 | - | - | 1 | 3 | 2 |
| Miscellaneous income | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 1 | 1 | 0 | 2 |
| Non-operating income | 1 | 1 | 34 | 50 | 36 | 11 | 3 | 1 | 3 | 3 | 4 |
| Interest expenses | - | - | - | 0 | 3 | - | - | 5 | 16 | 15 | 33 |
| Interest expenses on bonds | - | - | - | - | - | - | - | - | - | - | 2 |
| Share issuance costs | 7 | 4 | 0 | 5 | 22 | - | 5 | 2 | 5 | 4 | 2 |
| Commission expenses | - | - | - | 2 | - | - | - | 18 | - | 7 | 31 |
| Foreign exchange losses | 0 | - | - | 7 | - | 1 | 8 | 2 | 3 | 9 | 9 |
| Miscellaneous losses | - | 0 | - | 3 | 2 | - | 6 | 3 | 1 | 0 | 1 |
| Non-operating expenses | 16 | 5 | 0 | 16 | 28 | 1 | 14 | 27 | 24 | 36 | 78 |
| Ordinary profit (loss) | -374 | -517 | -790 | -786 | -1,177 | -903 | -816 | -1,187 | -991 | -953 | -625 |
| Gain on sale of investment securities | - | - | - | - | - | - | - | 4 | - | 418 | - |
| Gain on reversal of share acquisition rights | - | - | - | - | - | 1 | 8 | 1 | - | 1 | - |
| Extraordinary income | - | - | - | - | - | 1 | 8 | 6 | - | 419 | - |
| Loss on valuation of investment securities | - | - | - | - | 45 | - | - | - | - | - | 31 |
| Extraordinary losses | - | - | 0 | - | 45 | - | 46 | 6,133 | 9 | - | 31 |
| Profit (loss) before income taxes | -374 | -517 | -790 | -786 | -1,222 | -903 | -854 | -7,314 | -1,000 | -534 | -656 |
| Income taxes - current | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Income taxes | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Profit (loss) | - | - | -792 | -788 | -1,225 | -905 | -856 | -7,316 | -1,001 | -535 | -657 |